spacer
home > ebr > summer 2003 > preclinical juvenile toxicity studies: will it be safe for children?
PUBLICATIONS
European Biopharmaceutical Review

Preclinical Juvenile Toxicity Studies: Will it be Safe for Children?

The last issue of EPC highlighted the growth in paediatric clinical trials and difficulties in performing studies in children. Similar gaps in study cover have become an issue in preclinical studies and it is only in recent years that any studies have focused on the potential effects of direct treatment of young animals and on possible long-term effects.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Audrey Bottomley, David Myers and Chris Willoughby of the Reproductive Studies Group at Huntingdon Life Sciences

Audrey Bottomley is a UK Registered Toxicologist and the Principal Consultant Toxicologist to the Reproductive Studies Group with over 30 years' experience in reproductive and developmental toxicology. She is now primarily concerned with advising external clients and Huntingdon Life Sciences staff on the design and interpretation of reproductive studies.


David Myers is a Senior Study Director and Consultant Toxicologist within the Reproductive Studies Group. He has a PhD in age-related changes in the behaviour and brain of the ageing female mouse and is a specialist in the effects of treatments on behaviour in rodents. David is directly involved with study design management and interpretation in the developing field of behavioural testing.


Chris Willoughby is Head of the Reproductive Studies Group at Huntingdon Life Sciences and has qualifications in pharmacy and toxicology. He has worked in reproductive toxicology with Huntingdon Life Sciences since 1974 and has extensive experience managing studies of all types.

spacer
Chris Willoughby
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health invests for growth with the opening of its new Philadelphia-area office

PHILADELPHIA, PA – February 18, 2020: Signant Health, an industry-leading clinical research technology and solutions company, is proud to announce that it has officially opened a new, leading edge office facility in Blue Bell, Pennsylvania. Construction on the new office, which is the largest workplace in Signant Health’s global network, completed in February 2020.
More info >>

White Papers

ECCRT

ECCRT

The European Centre for Clinical Research Training (ECCRT) is a professional clinical research training provider focusing on the transfer of implementable knowledge for the day-to-day activities of our participants whether being new to the industry, starters on the job, or seasoned professionals. Our mission is to facilitate Clinical Research professionals to excel in their job for the benefit of patients. We aim to achieve this by providing clinical research professionals with competencies to develop new therapies for patients quicker & more efficiently, without jeopardizing quality and safety.
More info >>

 
Industry Events

Clinical Trial Supply Europe

11-12 March 2020, Madrid, Spain

The 21st annual edition promises to grow on the success of 2019’s excellent conference which saw delegates from Europe’s largest pharmaceutical companies and biotech innovators come together to discuss, debate and unpack the latest trends in clinical supply chain innovation. 2020 will offer delegates the opportunity to address the growing need for agility within the supply chain in response to increasingly complex trial demands. With a stream dedicated to supply operations and another to innovative uses of technology in the supply chain, delegates will get the chance to gain practical take-aways that they can apply to their own studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement